Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adamas Pharmaceuticals (ADMS) and Eli Lilly & Co (LLY).
Adamas Pharmaceuticals (ADMS)
In a report released today, Joshua Schimmer from Evercore ISI maintained a Buy rating on Adamas Pharmaceuticals, with a price target of $45.00. The company’s shares closed last Monday at $6.48.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.3% and a 53.4% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamas Pharmaceuticals with a $20.33 average price target, representing a 205.7% upside. In a report issued on December 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.
See today’s analyst top recommended stocks >>
Eli Lilly & Co (LLY)
In a report released today, Umer Raffat from Evercore ISI maintained a Hold rating on Eli Lilly & Co. The company’s shares closed last Monday at $119.64.
According to TipRanks.com, Raffat is a 2-star analyst with an average return of 1.2% and a 61.3% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Phathom Pharmaceuticals, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $132.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
